4//SEC Filing
Sundaram Preethi 4
Accession 0001161697-25-000422
CIK 0001369568other
Filed
Nov 23, 7:00 PM ET
Accepted
Nov 24, 8:08 PM ET
Size
13.8 KB
Accession
0001161697-25-000422
Insider Transaction Report
Form 4
Sundaram Preethi
Chief Strategy Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2025-11-21−5,603→ 811,959 total→ Common Stock (5,603 underlying) - Award
Options to purchase common stock
2025-11-20+106,873→ 785,305 totalExercise: $22.77Exp: 2032-11-20→ Common Stock (106,873 underlying) - Award
Restricted Stock Units
2025-11-20+32,257→ 817,562 total→ Common Stock (32,257 underlying) - Exercise/Conversion
Common Stock, par value $0.001 per share
2025-11-21+5,603→ 46,684 total - Tax Payment
Common Stock, par value $0.001 per share
2025-11-21−1,364→ 45,320 total
Footnotes (6)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- [F2]Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.
- [F3]Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.
- [F4]Shares of common stock will be delivered to the Reporting Person upon vesting.
- [F5]Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.
- [F6]Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.
Documents
Issuer
CATALYST PHARMACEUTICALS, INC.
CIK 0001369568
Entity typeother
Related Parties
1- filerCIK 0001872422
Filing Metadata
- Form type
- 4
- Filed
- Nov 23, 7:00 PM ET
- Accepted
- Nov 24, 8:08 PM ET
- Size
- 13.8 KB